MDT Stock Gains From FDA Approval for Its InPen App

Medtronic plc (MDT) recently received Food and Drug Administration (“FDA”) clearance for its new InPen app, which features missed meal dose detection. This latest FDA clearance should pave the way for the launch of the company’s Smart MDI system, which combines the InPen smart insulin pen with its newest Simplera continuous glucose monitor (CGM). Medtronic will initiate a limited market release with existing standalone CGM and InPen customers, followed by a broad commercial launch.   MDT’s Likely Stock Tren ...